Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, Lenvatinib, and GEMOX in Locally Advanced Biliary Tract Cancer
NCT05156788Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2021
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab in biliary tract cancer (BTC), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05156788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156788.